Leptomeningeal Metastases
Authors:
- 27 June 2012
- journal article
- research article
- Published by Springer Nature in Current Treatment Options in Neurology
- Vol. 14 (4) , 402-415
Abstract
Leptomeningeal cancer dissemination is a metastatic complication with growing impact in clinical oncology. Advances in treatment have been hampered by difficulties in diagnosis and response assessment, and nihilistic attitudes of physicians due to the poor prognosis, even when treating patients. However, relevant advances in therapeutic management have been achieved. In selected patients, survival and time to neurological progression can be improved with therapy, although an early diagnosis is critical (hence the importance of a high suspicion index). It is mandatory to perform an MRI of the entire neuraxis and cerebrospinal fluid (CSF) examination of up to two samples if the first lumbar puncture is negative, with appropriate volume and processing methods. It is advisable to supplement CSF analysis using flow cytometry techniques and new biomarker determinations (not yet validated) to improve diagnostic yield sensitivity. Currently, patients with good performance status and the option to receive effective systemic treatment must be treated with added intrathecal chemotherapy through Ommaya reservoirs and focal radiotherapy to bulky lesions or refractory painful areas. However, a standard treatment approach is not well-established due to the lack of well-designed randomized clinical trials and the mix of different cancer subtypes treated with the same drug in most studies. Liposomal cytarabine offers some advantages over methotrexate, both being first-line treatments for intrathecal administration. Recently, new agents have proven safe and feasible, broadening the available treatment options. The individualized choice of intrathecal agent based on the primary malignancy and appropriate treatment of underlying systemic disease are critical to improved outcomes in these patients.Keywords
This publication has 59 references indexed in Scilit:
- Role of flow cytometry immunophenotyping in the diagnosis of leptomeningeal carcinomatosisNeuro-Oncology, 2011
- Intrathecal gene therapy for treatment of leptomeningeal carcinomatosisJournal of Neuro-Oncology, 2010
- Prognostic factors and outcomes in patients with leptomeningeal melanomatosisNeuro-Oncology, 2008
- A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignanciesNeuro-Oncology, 2008
- Response and Resistance in a Non–Small-Cell Lung Cancer Patient With an Epidermal Growth Factor Receptor Mutation and Leptomeningeal Metastases Treated With High-Dose GefitinibJournal of Clinical Oncology, 2006
- Phase II trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitisCancer, 2006
- The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised studyEuropean Journal of Cancer, 2004
- A comparison between ventricular and lumbar cerebrospinal `uid cytology in adult patients with leptomeningeal metastasesNeuro-Oncology, 2001
- Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosisCancer Chemotherapy and Pharmacology, 2000
- Intrathecal immunotherapy in CNS tumors disseminating via CSF: preliminary evaluation using different treatment schedulesThe Italian Journal of Neurological Sciences, 1996